AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with

Authors

• Alex O Haber
• Aditi Jain
• Chinnadurai Mani
• Avinoam Nevler
• Lebaron C Agostini
• Talia Golan
• Komaraiah Palle
• Charles J Yeo
• William H Gmeiner
• Jonathan R Brody

Publication/Presentation Date

4-1-2021

Abstract

AraC-FdUMP[10] (CF10) is a second-generation polymeric fluoropyrimidine that targets both thymidylate synthase (TS), the target of 5-fluorouracil (5-FU), and DNA topoisomerase 1 (Top1), the target of irinotecan, two drugs that are key components of FOLFIRNOX, a standard-of-care regimen for pancreatic ductal adenocarcinoma (PDAC). We demonstrated that F10 and CF10 are potent inhibitors of PDAC cell survival (in multiple cell lines including patient-derived lines) with IC

Volume

19

Issue

4

First Page

565

Last Page

572

ISSN

1557-3125

Published In/Presented At

Haber, A. O., Jain, A., Mani, C., Nevler, A., Agostini, L. C., Golan, T., Palle, K., Yeo, C. J., Gmeiner, W. H., & Brody, J. R. (2021). AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Molecular cancer research : MCR, 19(4), 565–572. https://doi.org/10.1158/1541-7786.MCR-20-0985

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

33593942

Department(s)

Administration and Leadership

Document Type

Article